Endocannabinoid signaling regulates the reinforcing and psychostimulant effects of ketamine in mice

Xu, Wei; Li, Hongchun; Wang, Liang; Zhang, Jiamei; Liu, Chunqi; Wan, Xuemei; Liu, Xiaochong; Hu, Y.; Fang, Qiyao; Xiao, Yuanyuan; Bu, Qian; Wang, Hongbo; Tian, Jingwei; Zhao, Yinglan; Cen, Xiaobo

doi:10.1038/s41467-020-19780-z

Cited by 22 publications

(15 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have highlighted the association of PRDM5 with the progression of human cancers [ 19 , 33 , 34 ]. PRDM5 is a sequence-specific transcriptional repressor [ 35 ]. It has been shown that PRDM5 is silenced by promoter methylation in multiple cancers [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Hsa-let-7d-5p Promotes Gastric Cancer Progression by Targeting PRDM5

Gao

Liu

Wang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Gastric cancer (GC) is a common malignant tumor in the digestive system and a significant health burden worldwide. In this study, we found that hsa-let-7d-5p was upregulated in GC cells, promoted GC cell proliferation, migration, and invasion, and reduced apoptosis. Moreover, we found that the expression of PRDM5 (PR domain protein 5) was downregulated in GC cells and upregulated in GC cells treated with hsa-let-7d-5p inhibitor. Further investigation showed that hsa-let-7d-5p was the target of PRDM5, and the functions of hsa-let-7d-5p on GC progression were rescued by PRDM5 overexpression in GC cells. Collectively, our findings suggested that hsa-let-7d-5p promoted the development of GC by targeting PRDM5, indicating that hsa-let-7d-5p could be a promising therapeutic molecule for the treatment of gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Hsa-let-7d-5p Promotes Gastric Cancer Progression by Targeting PRDM5

Gao

Liu

Wang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…However, 2-AG concentrations were increased in CPu and NAcc, but decreased in PFC. Moreover, MGLL mRNA levels were reduced in CPu and PFC, although only MAGL protein expression in CPu was reduced [188]. Acute postnatal administration of PCP in mice reduced CB1R levels in the PFC, while increasing it in the dental gyrus of Hipp [189].…”

Section: Gene and Protein Function/expression Changes Of Ecs Componentsmentioning

confidence: 92%

Biomarkers of the Endocannabinoid System in Substance Use Disorders

et al. 2022

View full text Add to dashboard Cite

Despite substance use disorders (SUD) being one of the leading causes of disability and mortality globally, available therapeutic approaches remain ineffective. The difficulty in accurately characterizing the neurobiological mechanisms involved with a purely qualitative diagnosis is an obstacle to improving the classification and treatment of SUD. In this regard, identifying central and peripheral biomarkers is essential to diagnosing the severity of drug dependence, monitoring therapeutic efficacy, predicting treatment response, and enhancing the development of safer and more effective pharmacological tools. In recent years, the crucial role that the endocannabinoid system (ECS) plays in regulating the reinforcing and motivational properties of drugs of abuse has been described. This has led to studies characterizing ECS alterations after exposure to various substances to identify biomarkers with potential diagnostic, prognostic, or therapeutic utility. This review aims to compile the primary evidence available from rodent and clinical studies on how the ECS components are modified in the context of different substance-related disorders, gathering data from genetic, molecular, functional, and neuroimaging experimental approaches. Finally, this report concludes that additional translational research is needed to further characterize the modifications of the ECS in the context of SUD, and their potential usefulness in the necessary search for biomarkers.

show abstract

“…Brain tissue was collected immediately following cocaine preference testing and was prepared by using an ethyl acetate/hexane (9:1, v/v) extraction method adapted from a previously published study [ 21 ]. Tissues were spiked with ethyl acetate/hexane and internal standards (d4-AEA (10011178, Cayman) at 10 μg/mL; d5-2-AG (362,162, Cayman) at 100 μg/mL; 2 μL of mixed internal standards for each sample) and ultrasonicated in an ice-cold water bath.…”

Section: Methodsmentioning

confidence: 99%

“…Beginning 30 min before cocaine or saline administration, rimonabant and AM6545 (0.6 μg/μL, 1 μL/side, 0.5 μL/min) [ 21 ] as well as URB597 (10 ng/μL, 1 μL/side, 0.5 μL/min) [ 22 ] were administered bilaterally with a micro-injector. Beginning 15 min before cocaine or saline treatment, AEA (10 μM/side, 0.5 μL/min) was injected.…”

Section: Methodsmentioning

confidence: 99%